Akeso Biomedical, Inc. announced it raised $574,000 in an initial filing from an offering of $1 Million

Company

Location

About

Akeso Biomedical, Inc. is an early stage company focused on developing new solutions for the treatment of bacterial infections, microbial biofilms, and chronic wounds. The Company is developing products to treat these conditions using a new class of compounds, known as Fe3C, that have broad-spectrum activity against a wide range of bacteria, and a silk biomaterial technology exclusively licensed from Tufts University. Akeso’s lead Fe3C product is a feed additive designed to prevent food poisoning by Campylobacter, a bacteria that causes more cases of foodborne illness in the EU than Salmonella, E. coli and Listeria combined, with an estimated 280,000 cases in the UK and 1.3 million cases in the US each year. The economic cost of treating patients infected with Campylobacter in the UK is reported to be $1.5 billion, and over $5.6 billion in the US.